Richard J. Rebello
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Richard J. Rebello has a total of 131 co-authors. Here are the top co-authors by number of shared publications:
- Luc Furic
Peter MacCallum Cancer Centre, Melbourne, Australia
18 shared publications Arthi A. Macpherson
16 shared publications- Carleen Cullinane
Translational Research Laboratory, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia
16 shared publications Christina M. Fennell
16 shared publications- Helen B. Pearson
The European Cancer Stem Cell Research Institute, School of Biosciences, Cardiff University, Cardiff CF24 4HQ, UK
16 shared publications - Jason Li
Peter MacCallum Cancer Centre
16 shared publications
Latest Publications
- Open Access
- 20 May 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-15
Whole genome sequencing improves tissue-of-origin diagnosis and treatment options for cancer of unknown primary
Genomics can inform both tissue-of-origin (TOO) and precision treatments for patients with cancer of unknown primary (CUP). Here, we use whole genome and transcriptome sequencing (WGTS) for 72 patients and show diagnostic superiority of WGTS over panel testing (386–523 genes) in 71 paired cases. WGTS detects all reportable DNA features found by panel as well as additional mutations of diagnostic or therapeutic relevance in 76% of cases. Curated WGTS features and a CUP prediction algorithm (CUPPA) trained on WGTS data of known cancer types informs TOO in 71% of cases otherwise undiagnosed by clinicopathology review. WGTS informs treatments for 79% of patients, compared to 59% by panel testing. Finally, WGS of cell-free DNA (cfDNA) from patients with a high cfDNA tumour fraction (>7%), enables high-likelihood CUPPA predictions in 41% of cases. WGTS is therefore superior to panel testing, broadens treatment options, and is feasible using routine pathology samples and cfDNA.
- 20 May 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-15
Open AccessWhole genome sequencing improves tissue-of-origin diagnosis and treatment options for cancer of unknown primary
Genomics can inform both tissue-of-origin (TOO) and precision treatments for patients with cancer of unknown primary (CUP). Here, we use whole genome and transcriptome sequencing (WGTS) for 72 patients and show diagnostic superiority of WGTS over panel testing (386–523 genes) in 71 paired cases. WGTS detects all reportable DNA features found by panel as well as additional mutations of diagnostic or therapeutic relevance in 76% of cases. Curated WGTS features and a CUP prediction algorithm (CUPPA) trained on WGTS data of known cancer types informs TOO in 71% of cases otherwise undiagnosed by clinicopathology review. WGTS informs treatments for 79% of patients, compared to 59% by panel testing. Finally, WGS of cell-free DNA (cfDNA) from patients with a high cfDNA tumour fraction (>7%), enables high-likelihood CUPPA predictions in 41% of cases. WGTS is therefore superior to panel testing, broadens treatment options, and is feasible using routine pathology samples and cfDNA.
- Open Access
- 14 November 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-9
Unravelling mutational signatures with plasma circulating tumour DNA
The use of circulating tumour DNA (ctDNA) to profile mutational signatures represents a non-invasive opportunity for understanding cancer mutational processes. Here we present MisMatchFinder, a liquid biopsy approach for mutational signature detection using low-coverage whole-genome sequencing of ctDNA. Through analysis of 375 plasma samples across 9 cancers, we demonstrate that MisMatchFinder accurately infers single-base and doublet-base substitutions, as well as insertions and deletions to enhance the detection of ctDNA and clinically relevant mutational signatures.
- 14 November 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-9
Open AccessUnravelling mutational signatures with plasma circulating tumour DNA
The use of circulating tumour DNA (ctDNA) to profile mutational signatures represents a non-invasive opportunity for understanding cancer mutational processes. Here we present MisMatchFinder, a liquid biopsy approach for mutational signature detection using low-coverage whole-genome sequencing of ctDNA. Through analysis of 375 plasma samples across 9 cancers, we demonstrate that MisMatchFinder accurately infers single-base and doublet-base substitutions, as well as insertions and deletions to enhance the detection of ctDNA and clinically relevant mutational signatures.
- Open Access
Whole genome sequencing improves tissue of origin diagnosis and treatment options for cancer of unknown primary
Genomics holds promise for precision treatment and identifying the primary tissue of origin (TOO) in cases of cancer of unknown primary (CUP). We evaluated the feasibility and diagnostic superiority of whole genome and transcriptome sequencing (WGTS) over conventional panel testing in 72 patients using routine pathology samples. WGTS not only detected all reportable mutations identified by panel testing but also uncovered additional clinically relevant features in 76% of cases. Utilizing a CUP prediction algorithm (CUPPA) trained on WGTS data of known primary cancers, WGTS informed TOO in 77% of cases. Importantly, WGTS suggested potential treatment options for 79% of patients, a significant improvement over the 62% informed by panel testing. Additionally, WGTS and CUPPA applied to 22 cell-free DNA samples yielded high-likelihood TOO predictions in 41% of cases. These findings demonstrate that WGTS is diagnostically superior to panel testing, broadens treatment options, and is feasible using archived tissues and cell-free DNA.
Open AccessWhole genome sequencing improves tissue of origin diagnosis and treatment options for cancer of unknown primary
Genomics holds promise for precision treatment and identifying the primary tissue of origin (TOO) in cases of cancer of unknown primary (CUP). We evaluated the feasibility and diagnostic superiority of whole genome and transcriptome sequencing (WGTS) over conventional panel testing in 72 patients using routine pathology samples. WGTS not only detected all reportable mutations identified by panel testing but also uncovered additional clinically relevant features in 76% of cases. Utilizing a CUP prediction algorithm (CUPPA) trained on WGTS data of known primary cancers, WGTS informed TOO in 77% of cases. Importantly, WGTS suggested potential treatment options for 79% of patients, a significant improvement over the 62% informed by panel testing. Additionally, WGTS and CUPPA applied to 22 cell-free DNA samples yielded high-likelihood TOO predictions in 41% of cases. These findings demonstrate that WGTS is diagnostically superior to panel testing, broadens treatment options, and is feasible using archived tissues and cell-free DNA.
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Figure S1 from Identification of Pik3ca Mutation as a Genetic Driver of Prostate Cancer That Cooperates with Pten Loss to Accelerate Progression and Castration-Resistant Growth
Supplementary Figure 1: PIK3CA mutations are predominantly missense mutations and PTEN mutation/loss predicts for poor prostate cancer patient survival. (A) Pie chart depicting the frequency of missense/nonsense mutations, in-frame deletions and fusion events in PIK3CA identified in the 9 prostate cancer genomic datasets assessed in Fig. 1A (3-10). (B) Kaplan-Meier plot comparing TCGA provisional prostate adenocarcinoma dataset with PTEN homozygous deletion, loss or mutation compared to the general population. PTEN age-adjusted COXPH HR: 0.47, P = 0.0026* (n = 492, samples with sequencing and CNA data only). Data was obtained from the TCGA data portal (https://tcga-data.nci.nih.gov/). PTEN copy number loss criteria; Log R ratio {less than or equal to} -0.48, probe number {greater than or equal to} 10. Silent mutations were excluded.
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from Identification of Pik3ca Mutation as a Genetic Driver of Prostate Cancer That Cooperates with Pten Loss to Accelerate Progression and Castration-Resistant Growth
Supplementary Figure 1: PIK3CA mutations are predominantly missense mutations and PTEN mutation/loss predicts for poor prostate cancer patient survival. (A) Pie chart depicting the frequency of missense/nonsense mutations, in-frame deletions and fusion events in PIK3CA identified in the 9 prostate cancer genomic datasets assessed in Fig. 1A (3-10). (B) Kaplan-Meier plot comparing TCGA provisional prostate adenocarcinoma dataset with PTEN homozygous deletion, loss or mutation compared to the general population. PTEN age-adjusted COXPH HR: 0.47, P = 0.0026* (n = 492, samples with sequencing and CNA data only). Data was obtained from the TCGA data portal (https://tcga-data.nci.nih.gov/). PTEN copy number loss criteria; Log R ratio {less than or equal to} -0.48, probe number {greater than or equal to} 10. Silent mutations were excluded.
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Figure S3 from Identification of Pik3ca Mutation as a Genetic Driver of Prostate Cancer That Cooperates with Pten Loss to Accelerate Progression and Castration-Resistant Growth
Supplementary Figure 3: Characterization of Pik3ca-mutated and Pten-deleted prostate hyperplasia and carcinoma. (A) IHC to detect the apoptotic marker Cleaved-Caspase-3 (CC3) in Wt, Pik3ca+/HR and Ptenfl/fl mice at 400 d (scale bar: 50 um). (B) Quantitation of CC3-positive nuclei in Wt, Pik3ca+/HR and Ptenfl/fl prostate epithelium (n = 3, *P <0.05 compared to Wt, or as indicated, one-way ANOVA with Tukey's multiple comparison test, ns = not significant. Error bars: SEM). (C) IHC to detect CK5 and CK8 in Pik3ca+/HR and Ptenfl/fl carcinomas (representative images from 3 prostates per genotype, scale bar: 50 um). (D) Representative IHC images to detect PTEN, mTORC1 signaling components (p-AKT Thr308, p-RPS6 Ser235/236 and p-4E-BP1 Thr37/46) and mTORC2 substrates (p-AKT Ser473 and p-NDRG1 Thr346) in Pik3ca+/HR and Ptenfl/fl hyperplastic lesions (n = 3, scale bar: 50 um). IHC quantitation for (E) p-AKT Thr308, (F) p-RPS6 Ser235/236, (G) p-4E-BP1 Thr37/46, (H) p-AKT Ser473 and (I) p-NDRG1 Thr346 in Pik3ca+/HR and Ptenfl/fl prostate hyperplastic lesions (n = 3, Error bars: SEM, *P < 0.05, unpaired, two-tailed t-test).
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from Identification of Pik3ca Mutation as a Genetic Driver of Prostate Cancer That Cooperates with Pten Loss to Accelerate Progression and Castration-Resistant Growth
Supplementary Figure 3: Characterization of Pik3ca-mutated and Pten-deleted prostate hyperplasia and carcinoma. (A) IHC to detect the apoptotic marker Cleaved-Caspase-3 (CC3) in Wt, Pik3ca+/HR and Ptenfl/fl mice at 400 d (scale bar: 50 um). (B) Quantitation of CC3-positive nuclei in Wt, Pik3ca+/HR and Ptenfl/fl prostate epithelium (n = 3, *P <0.05 compared to Wt, or as indicated, one-way ANOVA with Tukey's multiple comparison test, ns = not significant. Error bars: SEM). (C) IHC to detect CK5 and CK8 in Pik3ca+/HR and Ptenfl/fl carcinomas (representative images from 3 prostates per genotype, scale bar: 50 um). (D) Representative IHC images to detect PTEN, mTORC1 signaling components (p-AKT Thr308, p-RPS6 Ser235/236 and p-4E-BP1 Thr37/46) and mTORC2 substrates (p-AKT Ser473 and p-NDRG1 Thr346) in Pik3ca+/HR and Ptenfl/fl hyperplastic lesions (n = 3, scale bar: 50 um). IHC quantitation for (E) p-AKT Thr308, (F) p-RPS6 Ser235/236, (G) p-4E-BP1 Thr37/46, (H) p-AKT Ser473 and (I) p-NDRG1 Thr346 in Pik3ca+/HR and Ptenfl/fl prostate hyperplastic lesions (n = 3, Error bars: SEM, *P < 0.05, unpaired, two-tailed t-test).